Journal article icon

Journal article

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.

Abstract:

Proteasome inhibitors, such as the dipeptide boronic acid bortezomib, are emerging as important tools in the treatment of the fatal hematologic malignancy multiple myeloma. Despite the recent US Food and Drug Administration approval of bortezomib (PS341, Velcade) for the treatment of refractory multiple myeloma, many of the basic pharmacologic parameters of bortezomib and its mode of action on myeloma cells remain to be determined. We describe the synthesis and use of a cell-permeant active s...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/nmeth759

Authors


Expand authors...
Journal:
Nature methods
Volume:
2
Issue:
5
Pages:
357-362
Publication date:
2005-05-05
DOI:
EISSN:
1548-7105
ISSN:
1548-7091
URN:
uuid:682f406a-f96d-4878-8fee-48ea7b2cbe2f
Source identifiers:
25950
Local pid:
pubs:25950

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP